Company news
Vivos Therapeutics, Inc. news in 2026
Vivos Therapeutics, Inc.'s news releases, calls and decks from 2026, newest first.
CORRECTION: SOD Sciences Welcomes Vivos Therapeutics as Strategic Investor and Partner in the ReBalU Primed Cell Test
October 29, 2026
Vivos Therapeutics Reports Nasdaq Confirmation of Compliance with Continued Listing Shareholders’ Equity Standard
October 21, 2026
SOD Sciences Welcomes Vivos Therapeutics as Strategic Investor and Partner in the ReBalU Primed Cell Test
October 20, 2026
Vivos Therapeutics Closes Acquisition of Stake in SOD Sciences and 50% Interest in Pseudohypoxia Test, Opening a Potential Path to Access More Than 325,000 New Patients Through the AHA Channel
October 19, 2026
Vivos Therapeutics Agrees to Acquire Minority Stake in SOD Sciences and 50% Interest in Proprietary Pseudohypoxia Test
October 15, 2026
Vivos Therapeutics Reports Progress in Material Cost Reductions and Revenue Growth Initiatives
September 29, 2026
Vivos Therapeutics Announces Material Debt Reduction
September 8, 2026
Vivos Therapeutics to Present at the 2026 Moody Capital Solutions Disruptive Growth & Life Sciences Conference
September 1, 2026
Vivos Therapeutics and South Palm Cardiovascular Associates Sign Definitive Agreements to Launch Regional Sleep Testing and Treatment Center
August 28, 2026
Vivos Therapeutics Reports Record New Patient Referrals at its Nevada Sleep & Airway Medicine Centers
August 25, 2026
Vivos Therapeutics Opens New Sleep Testing and Treatment Facility in Nevada to Meet Rapidly Growing Patient Demand for Sleep Apnea Testing and Treatment
August 20, 2026
Vivos Therapeutics Schedules Release of Second Quarter 2026 Financial Results and Conference Call
August 14, 2026
Vivos Therapeutics Announces Issuance of New US Patent Broadening Protection for Its Vivos CARE Oral Medical Device Technology
August 5, 2026
Vivos’ Vida® Appliance Shows Statistically Significant Improvement in Insomnia Severity in 100% of Study Participants
June 30, 2026
Vivos Therapeutics and Streeterville Extend Timeframe of Strategic Financing Agreement and Reaffirm Commitment to Convert Debt Into Common Stock and Perpetual Preferred Equity
June 22, 2026
Vivos Therapeutics Announces Intent to File a Registration Statement for a Proposed Rights Offering
June 11, 2026
Vivos Therapeutics Announces Key Collaboration Agreement with Multi-Location Florida Cardiology Group to Extend Much Needed Sleep Apnea and Insomnia Diagnosis and Treatment to Cardiovascular Patients
June 10, 2026
Vivos Therapeutics To Participate in the Small Cap Showcase & WTR Insights on June 9, 2026
June 7, 2026
Vivos Therapeutics Announces Binding Agreement for Senior Debt-to-Equity Exchange of Up to $4.5 Million from Streeterville Capital to Support Continued Nasdaq Listing
June 4, 2026
Vivos Therapeutics Reports First Quarter 2026 Financial Results and Provides Operational Update
May 20, 2026
Vivos Therapeutics Reports Full Year 2025 Financial Results
April 15, 2026
Vivos Therapeutics Schedules Release of Full Year 2025 Financial Results and Conference Call
April 15, 2026
Vivos Therapeutics Completes Private Placement with Existing Private Equity Investor, New Seneca Partners
April 6, 2026
Vivos Therapeutics Reports that Supported Professional Practices Have Achieved 'In-Network' Status Across Multiple Commercial Health Insurers and Medicare in Key Nevada Market
March 26, 2026
Recent Study Confirms Fundamental Correlation Between Severity of Obstructive Sleep Apnea and Oral Anatomy
March 17, 2026
Vivos Therapeutics and SoundHealth Announce Collaboration to Expand Access to SoundHealth’s Groundbreaking FDA-Cleared Allergy and Sleep Technologies
February 5, 2026
VIVOS Therapeutics, Inc. ($VVOS) Signs 12-Part Media Series with New to The Street
February 5, 2026
Vivos Therapeutics Announces Closing of Exercise of Warrants for $4.64 Million Gross Proceeds
January 20, 2026
Vivos Therapeutics Announces Exercise of Warrants for $4.64 Million Gross Proceeds
January 16, 2026